Olanzapine NDC 72303-0840

NDC codes

FDA NDC Directory

Product NDC (as listed)72303-0840Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72303-0840Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72303-0840-1	72303084001	30 TABLET in 1 BOTTLE, PLASTIC (72303-0840-1)Marketed from Nov 30, 2018

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Olanzapine
Generic name (nonproprietary): olanzapine
Active ingredients: Olanzapine — 20 mg/1
Dosage form: Tablet
Route: Oral
Labeler: HEC Pharm USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206238
Marketing start: Nov 30, 2018
Listing expires: Dec 31, 2027
Identifiers: Product ID 72303-0840_4d2e9776-65f4-cb00-e063-6394a90a1bf7SPL ID 4d2e9776-65f4-cb00-e063-6394a90a1bf7SPL set ID 4d34f8f3-edc8-0a68-e063-6394a90a9c1fRxCUI 200034, 283639, 312077, 312078, 312079, 314154UNII N7U69T4SZRUPC 0372303083616, 0372303083913, 0372303083814
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472303084001 followed by a unit qualifier and the quantity

Package 72303-0840-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 16, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13 years to 17 years): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206238

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206238
Product	Strength	Form · route	Labeler	Product NDC
Olanzapine	Olanzapine 2.5 mg/1	TabletOral	HEC Pharm USA Inc.	72303-0835
Olanzapine	Olanzapine 15 mg/1	TabletOral	HEC Pharm USA Inc.	72303-0839
Olanzapine	Olanzapine 5 mg/1	TabletOral	HEC Pharm USA Inc.	72303-0836
Olanzapine	Olanzapine 7.5 mg/1	TabletOral	HEC Pharm USA Inc.	72303-0837
Olanzapine	Olanzapine 10 mg/1	TabletOral	HEC Pharm USA Inc.	72303-0838